⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LGND News
Ligand Pharmaceuticals Inc.
XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA
businesswire.com
XOMA
LGND
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
prnewswire.com
XOMA
LGND
Form 8-K
sec.gov
LGNDZ
LGND
LGNXZ
LGNYZ
LGNZZ
XOMA
Form 8-K
sec.gov
XOMAO
XOMAP
XOMA
LGND
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
globenewswire.com
LGND
XOMA
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
globenewswire.com
LGND
XOMA
Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
globenewswire.com
LGND
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
globenewswire.com
TVTX
LGND
Form 8-K
sec.gov
SKYE
LGND
Frontier Medicines Announces Exclusive Licensing Agreement for FMC-220, a First-in-Class Covalent p53 Y220C Activator, with LG Chem, Ltd.
businesswire.com
LGND